Table 1.
Summary of currently available KMO inhibitors
| KMO inhibitor | IC50 (nM)a | Structures | Refs |
|---|---|---|---|
| m-NBA | 900b | ![]() |
[61] |
| Ro 61-8048 | 37b | ![]() |
[62] |
| UPF-648 | 40 | ![]() |
[63] |
| JM6 | 37b, c | ![]() |
[64] |
| CHDI-340246 | 0.5 | ![]() |
[65] |
| GSK180 | 6 | ![]() |
[66] |
| Prodrug 1b | 2600d | ![]() |
[67] |
IC50 values are for inhibition of human KMO unless stated otherwise.
IC50 with rat KMO.
The IC50 value for JM6 relates to the IC50 of the active compound Ro 61-8048 following release from the prodrug. Subsequent analyses of JM6 led to debate over this prodrug mechanism [68].
The IC50 value for prodrug 1b relates to the IC50 of the active compound 1 following release from the prodrug.






